Adverum Biotechnologies
Biotechnology ResearchView the employees at
Adverum Biotechnologies-
Helen Gebremicael Quality Control Analyst IV at Adverum Biotechnologies, Inc.
-
San Jose, California, United States
-
Top 5%
Michael Friedman Clinical Development and Medical Affairs Leadership in Gene Therapy, Retinal Disease, Rare Disease, and Inflammatory Disease-
San Rafael, California, United States
-
Top 10%
Seung Kim Senior Analyst, IT Infrastructure & Security at Adverum Biotechnologies, Inc.-
Rocklin, California, United States
-
Rising Star
Leily Daneshian Scientist at Adverum Biotechnologies, Inc.-
United States
-
Rising Star
Cameron Baker Scientist at Adverum Biotechnologies, Inc.-
Berkeley, California, United States
-
Rising Star
Overview
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
-